BfArM
- Local brand name: Alhemo
- Status: approved
Alhemo (CONCIZUMAB) regulatory status in Germany.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. BfArM has authorised it.
Novo Nordisk Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.